Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD

BACKGROUND: Recent evidence suggests the systemic accumulation of by-products of gut microbes contributes to cardiovascular morbidity in patients with CKD. Limiting the generation of toxic bacterial by-products by manipulating the intestinal microbiota may be a novel strategy for reducing cardiovasc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Kidney360
Main Authors: Kimber, Cassandra, Zhang, Shiqin, Johnson, Cassandra, West, Raymond E., Prokopienko, Alexander J., Mahnken, Jonathan D., Yu, Alan S., Hoofnagle, Andrew N., Ir, Diana, Robertson, Charles E., Miyazaki, Makoto, Chonchol, Michel, Jovanovich, Anna, Kestenbaum, Bryan, Frank, Daniel N., Nolin, Thomas D., Stubbs, Jason R.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Nephrology 2020
Assuntos:
Original Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8315698/
https://ncbi.nlm.nih.gov/pubmed/34322673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.34067/KID.0003942020
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados